Subacute CNS Demyelination After Treatment With Immune Checkpoint Inhibitors

In a patient who develops neurologic symptoms while taking immune checkpoint inhibitors such as pembrolizumab, do consider CNS demyelination as a differential diagnosis.

Source: Neurology Clinical Practice - December 13, 2021 Category: Neurology Authors: Tan, E., Shaw, H., Nathan, P., Ghosh-Ray, S., Ottaviani, D. Tags: MRI, All Clinical Neurology, All Oncology, All Demyelinating disease (CNS) Case Source Type: research